mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells

High activity of the mechanistic target of rapamycin (mTOR) is associated with poor prognosis in pre-B-cell acute lymphoblastic leukemia (B-ALL), suggesting that inhibiting mTOR might be clinically useful. However, emerging data indicate that mTOR inhibitors are most effective when combined with oth...

Descripción completa

Detalles Bibliográficos
Autores principales: Beagle, Brandon R., Nguyen, Duc M., Mallya, Sharmila, Tang, Sarah S., Lu, Mengrou, Zeng, Zhihong, Konopleva, Marina, Vo, Thanh-Trang, Fruman, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385838/
https://www.ncbi.nlm.nih.gov/pubmed/25576920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385838/
https://www.ncbi.nlm.nih.gov/pubmed/25576920

Ejemplares similares